Idelalisib (Zydelig(R)) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia
Rothschedl E, Joppi R, Poggiani C
Record ID 32015000387
English
Authors' recommendations:
In conclusion, combination therapy of idelalisib and rituximab offers a new treatment option for patients with relapsed CLL who are ineligible for cytotoxic therapy; particularly for those with genetic factors including 17p deletion, TP53 mutation or unmutated IGHV. Nevertheless, further trials are needed to evaluate efficacy and safety in the long-term use of idelalisib, as well as the important issue of potential idelalisib resistance.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://eprints.hta.lbg.ac.at/1044/1/DSD_HSO_Nr.49.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Antibodies, Monoclonal
- Leukemia, Lymphocytic, Chronic, B-Cell
- Rituximab
- Antineoplastic Combined Chemotherapy Protocols
- Enzyme Inhibitors
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.